A large series of patients with various tumor histologies showed that the presence of the PIK3CA p.H1047R mutation specifically was an independent predictor for tumor response to PI3K pathway inhibitors.38 All 4 of our patients with PIK3CA mutations had this particular mutation, and one had a concurrent PIK3CA p.E542A mutation. The gene discussed is PIK3CA; the disease is neoplasm.